Table 2.
Adverse events (AEs) occurred in >3% of patients during abiraterone treatmenta
| Total number of patients with AEs (n = 244) n (%) |
||||
|---|---|---|---|---|
| Mild | Moderate | Severe | Total | |
| Asthenia | 31 (12.7) | 5 (2.0) | 2 (0.8) | 38 (15.6) |
| Diarrhea | 17 (7.0) | 1 (0.4) | 0 (0.0) | 18 (7.4) |
| Edema | 13 (5.3) | 5 (2.0) | 0 (0.0) | 16 (6.6) |
| Fatigue | 12 (4.9) | 3 (1.2) | 1 (0.4) | 16 (6.6) |
| Fever | 13 (5.3) | 2 (0.8) | 1 (0.4) | 16 (6.6) |
| Anemia | 9 (3.7) | 4 (1.6) | 3 (1.2) | 15 (6.1) |
| Dyspnea | 11 (4.5) | 4 (1.6) | 0 (0.0) | 15 (6.1) |
| Nausea | 10 (4.1) | 4 (1.6) | 1 (0.4) | 13 (5.3) |
| Cough | 10 (4.1) | 1 (0.4) | 0 (0.0) | 11 (4.5) |
| Constipation | 7 (2.9) | 3 (1.2) | 1 (0.4) | 10 (4.1) |
| Pain | 9 (3.7) | 2 (0.8) | 0 (0.0) | 10 (4.1) |
| Death unexpected | 0 (0.0) | 0 (0.0) | 9 (3.7) | 9 (3.7) |
a
Including AEs with onset within 30 days after abiraterone permanent discontinuation.